US › Healthcare

NervGen Pharma Corp. (NGEN)

US · Healthcare · Biotechnology

$1.66+1.22%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-1.7M

Profit YoY

+56.6%

EPS

$-0.07

EPS estimate

$-0.06

EPS came in at -0.07 against a street estimate of -0.06 — a miss of 11.8%.

Key statistics

Market cap

$172.4M

Forward P/E

0.0

P/B

68.74

Book value

$0.05

EPS (TTM)

$-0.46

52-week high

$6.30

52-week low

$1.58

50-day MA

$1.96

200-day MA

$3.47

Beta

0.69

Analyst view

with an average price target of $10.60.

Shareholding

Insiders

15.73%

Institutions

1.64%

Largest institutional holders

Fund	Stake
PFG Investments, LLC	0.20%
Bank of America Corp	0.19%
Marshall Wace Asset Management Ltd	0.19%
Royal Bank of Canada	0.16%
Integrated Wealth Concepts LLC	0.08%
VALLEY FORGE INVESTMENT CONSULTANTS INC ADV	0.07%
Bank of Montreal	0.06%
BMO Capital Markets Corp.	0.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for NervGen Pharma Corp. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.